Posted on 1/24/17
FamilyWize’s New Medicine Cabinet Feature Allows Users to Personalize Their Prescription Drug Price Search on Their Website
FamilyWize announced today the release of the Medicine Cabinet, the next evolution of its Drug Price Lookup Tool. With the Medicine Cabinet, users will have the . . .
Posted on 1/23/17
Teva Has Got Potential - And The Complexity To Go With It
When Teva Pharmaceutical (NYSE:TEVA) acquired the Actavis generic drug business from Allergan (NYSE:AGN) in August 2016, the Company not only paid a big financial price ($40.5 . . .
Posted on 1/23/17
Johnson & Johnson Earnings Preview: Don't Expect Big Surprises
Johnson & Johnson (NYSE:JNJ) will report its Q4 2016 earnings on Tuesday, January 24th. We expect mild growth driven primarily by the pharma business, which continues . . .
Posted on 1/23/17
Better Buy: GlaxoSmithKline PLC vs. Johnson & Johnson
Two big drugmakers have seen their stocks go in opposite directions over the last five years. GlaxoSmithKline (NYSE:GSK) shareholders lost more than 10% during the period, . . .
Posted on 1/23/17
Can Johnson & Johnson Sustain Its Growth in 2017?
Johnson & Johnson (NYSE:JNJ) has become a colossus in the healthcare industry with its exposure to the pharmaceutical, medical device, and consumer over-the-counter health-products markets combining . . .
Posted on 1/23/17
How Will Pfizer Inc. Fare Under President Trump?
President Trump could shake up the pharmaceutical world. If he delivers on his promises, it means that Pfizer (NYSE:PFE), one of the biggest of the big . . .
Posted on 1/23/17
Better Buy: Merck & Co. Inc. vs. Pfizer
Merck (NYSE:MRK) and Pfizer (NYSE:PFE) compete against each other in several markets, from cancer to vaccines. The big drugmakers also work together from time to time. . . .
Posted on 1/23/17
Top Biotech Stocks to Buy in 2017
The past 18 months haven't been very pleasant for biotech investors. The SPDR S&P Biotech ETF (NYSEMKT:XBI) has fallen nearly 30% from its all-time highs set . . .
Posted on 1/23/17
Should You Be Afraid of Huge Medicare Changes Under President Trump?
You've probably seen headlines warning that Republicans want to radically change Medicare. Potentially alarming words like "privatization" have been thrown around. Should you be afraid of . . .
Posted on 1/23/17
Bristol-Myers Squibb and Ono Pharmaceutical Company Enter Settlement and License Agreement with Merck
NEW YORK & OSAKA, Japan--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Ono Pharmaceutical Company, Ltd. today announced the companies have signed a global patent license agreement with . . .
Posted on 1/20/17
Amarin Announces Debt Restructuring
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 20, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN) announced today that it and its wholly owned subsidiary, Corsicanto II . . .
Posted on 1/20/17
Egalet: A Promising Company Currently On Sale
IntroductionEgalet (NASDAQ:EGLT) is a pharmaceutical company focused on developing and marketing treatments to address the needs of patients living with pain. While pain management is important, . . .
Posted on 1/19/17
Matinas BioPharma Completes Warrant Tender Offer – Raises $13.5 Million from Exercise of Warrants
BEDMINSTER, N.J., Jan. 19, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, announced . . .
Posted on 1/19/17
Decisio Health Selects Resound Marketing as Public Relations Agency of Record
Resound Marketing, helping companies "make some noise" through results-driven PR and marketing programs, today announced it has been selected as the PR agency of record for . . .
Posted on 1/19/17
5 Most Important Drugs to Johnson & Johnson in 2017
Johnson & Johnson (NYSE:JNJ) generates billions of dollars by selling consumer goods and medical devices, but its pharmaceuticals business is the one that's most likely to . . .
Posted on 1/19/17
Zynerba Pharmaceuticals Announces Proposed Public Offering of Common Stock
DEVON, Pa., Jan. 18, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid . . .
Posted on 1/19/17
Egalet Closes Second Tranche of $80 Million Secured Debt Financing
Egalet Corporation (Nasdaq: EGLT), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced the . . .
Posted on 1/18/17
Better Buy: Amgen Inc. vs. Celgene Corporation
While 2016 wasn't the best year for Amgen (NASDAQ:AMGN) and Celgene(NASDAQ:CELG), both big biotech stocks have been tremendous winners over the last several years for investors. . . .
Posted on 1/18/17
Should Pfizer, Inc. Be on Your Stock Watchlist?
Pfizer, Inc. (NYSE:PFE) is one of the largest drugmakers in the world, and management is making solid progress in kick-starting sales and profit growth following years . . .
Posted on 1/17/17
Health Partners Plans Names Matthew Post VP of Medicare Sales
Health Partners Plans (HPP) announced today that veteran health care leader Matthew Post joined the company
Posted on 1/17/17
Nursing Shortage Inspires Action at BAYADA Home Health Care
Bureau of Labor Statistics predicts 1 million nurses will be needed by 2022BAYADA Home Health Care, which provides a complete continuum of in-home care services, is . . .
Posted on 1/17/17
Is Donald Trump Big Pharma's Worst Nightmare?
President-elect Donald Trump pulled no punches when it came to big pharma in a press conference on Wednesday: He said that pharmaceutical companies "are getting away . . .
Posted on 1/17/17
Trumpcare, Not Obamacare, Could Be a Job Killer
IMAGE SOURCE: DISNEY-ABC TELEVISION GROUP, FLICKR.In less than one week's time Donald Trump is set to become the 45th president of the United States, which seemed . . .
Posted on 1/17/17
Does Johnson & Johnson Pass the Buffett Test?
Many smart investors use checklists to help them vet potential investment ideas. This strategy is even used by famed investor Warren Buffett before he makes multibillion-dollar . . .
Posted on 1/16/17
Akers Biosciences Closes Public Offering
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR), a developer of rapid health information technologies, today announces the closing of its previously announced underwritten public offering of . . .
Philadelphia
